Clinical trials: High-Risk Cancer, open to volunteers
Prostate Cancer
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment.
- Trial name
- NCT07184970
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer…
- Conditions
- Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT04725903
- Testing
- High-Dose Rate Brachytherapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Trial name
- TPG (NCT07502872)
- Testing
- Tafasitamab, Polatuzumab vedotin, Glofitamab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Endometrial Cancer, Endometrial Carcinoma (EC)
Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer
This multicenter retrospective observational cohort study aims to evaluate the prognosis of patients with non-myoinvasive endometrial cancer harbouring high-risk molecular features by determining the rate of lymph node…
- Conditions
- Endometrial Cancer, Endometrial Carcinoma (EC), p53abn
- Trial name
- MyoNone (NCT07838207)
- Where
- Spain
- Volunteers
- 350 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Lung Cancer (NSCLC)
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
- Trial name
- STRADOS (NCT07432802)
- Testing
- Stereotactic radiation therapy intervention, Surgical intervention
- Where
- 4 sites in Denmark
- Volunteers
- 182 people
- Sponsor
- Aarhus University Hospital
Prostate Cancer, Locally Recurrent Cancer
Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and…
- Conditions
- Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation
- Trial name
- PROSCATE (NCT07860528)
- Where
- 10 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Colorectal Cancer Control and Prevention, Colorectal Cancer
Prophylactic PIPAC in Patients With High-risk Colorectal Cancer
In a multicentric randomized controlled trial, we will compare standard surgery (consisting in removal of the primary cancer) followed by 6 months of adjuvant chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- PROPAC (NCT06839092)
- Testing
- oxaliplatin-based PIPAC, Control (Standard treatment)
- Volunteers
- 160 people
- Sponsor
- Jeremy Meyer
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Multimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard…
- Trial name
- FOBEAR (NCT04215731)
- Testing
- Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Restaging, Concomitant Chemoradiotherapy
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Yanhong Deng
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant…
- Trial name
- NCT06613100
- Testing
- Xaluritamig, GnRH Antagonist
- Where
- 9 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Amgen
Early Gastric Cancer
Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
The pathological biopsy of gastric lesions, performed prior to endoscopic submucosal dissection (ESD), is crucial for differentiating the pathological nature of the lesions and guiding treatment decisions.
- Trial name
- pCLE (NCT07507071)
- Testing
- Probe-based Confocal Laser Endomicroscopy, Pathological biopsy
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Changhai Hospital
Extensive-stage Small Cell Lung Cancer
Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
This study is expected to enroll 182 patients with partial response or stable disease after first-line immunochemotherapy for extensive-stage small cell lung cancer and eligible for thoracic consolidation radiotherapy within 2…
- Trial name
- NCT06719336
- Testing
- High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy, atezolizumab or durvalumab
- Volunteers
- 182 people
- Sponsor
- Anhui Shi, MD
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
- Trial name
- QUEEN-Dream (NCT06404736)
- Testing
- Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Supplemental Oxygen, Gynecological Cancer
Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients
The incidence of surgical-site infection (SSI) and complications related to wound healing reaches 10-20% of gynecological cancer patients.
- Conditions
- Supplemental Oxygen, Gynecological Cancer, Surgical Site Infections
- Trial name
- SAFE (NCT06780813)
- Testing
- Supplemental oxygen therapy
- Where
- Greece
- Volunteers
- 400 people
- Sponsor
- National and Kapodistrian University of Athens
Prostate Cancer
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI).
- Trial name
- HypoElect (NCT06582446)
- Testing
- Androgen Deprivation Therapy (ADT) - Goserelin, High-Dose-Rate Interstitial Brachytherapy (HDR BRT), radiotherapy
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic onabotulinumtoxinA (BOTOX®) administered before radical…
- Trial name
- NCT07796490
- Testing
- OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic…
- Trial name
- LIBRA (NCT06982924)
- Testing
- Limertinib+bevacizumab, Limertinib
- Volunteers
- 136 people
- Sponsor
- Shanghai Chest Hospital
Prostate Cancer, Magnetic Resonance Imaging
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Population at Risk
- Trial name
- NCT05384535
- Testing
- Bi-parametric MRI
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.